You are here: Industry Insights > Glenmark

News List

Glenmark initiates Phase 3 clinical trials on antiviral Favipiravir expresspharma
May 13, 2020
Over 10 leading government and private hospitals in India are being enrolled for the study, Glenmark estimates study completion by July/August 2020.
DCGI approves Glenmark’s clinical trials of Favipiravir Antiviral tablets for COVID-19 patients expresspharma
April 30, 2020
The product is a generic version of Avigan of Fujifilm Toyama Chemical, Japan, a subsidiary of Fujifilm Corporation.
Glenmark announces approval for Ryaltris in Australia biospectrumasia
December 22, 2019
Glenmark Pharmaceuticals has announced that Seqirus Pty. Ltd. (Seqirus) has received marketing approval for Ryaltris® from the Therapeutic Goods Administration (TGA), Australia. This paves the way for the launch of Ryaltris® in Australia through the partn
Glenmark Recalls All Unexpired Lots of its Ranitidine Tablets, Ceases Distribution americanpharmaceuticalreview
December 19, 2019
Glenmark Pharmaceutical announced the voluntary recall of all unexpired lots of Ranitidine Tablets, 150 mg and 300 mg, to the consumer level.
Glenmark receives Orphan Drug Designation for GBR 1342 biospectrumasia
September 18, 2019
Derived from the company’s proprietary BEAT® (Bispecific Engagement by Antibodies based on the T cell receptor) technology, GBR 1342 is being investigated for the treatment of multiple myeloma.
Glenmark Receives Orphan Drug Designation for Multiple Myeloma Candidate americanpharmaceuticalreview
September 18, 2019
Glenmark announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its bispecific antibody candidate GBR 1342 for the treatment of patients with multiple myeloma ...
Glenmark Receives ANDA Approval for Pimecrolimus Cream, 1% americanpharmaceuticalreview
September 03, 2019
Glenmark Pharmaceuticals has been granted final approval by the United States Food & Drug Administration (FDA) for Pimecrolimus Cream, 1%, a generic version of Elidel® Cream, 1%, of Bausch Health US.
Glenmark receives approval to market Remogliflozin and Metformin combination drug expresspharma
August 21, 2019
Glenmark Pharmaceuticals recently announced that the company has received regulatory approval to market a combination of its novel, patent protected and globally-researched sodium glucose ...
Glenmark Receives Approval for Combination of Remogliflozin Etabonate and Metformin Hydrochloride for Adults with Type 2 Diabetes in India americanpharmaceuticalreview
August 20, 2019
Glenmark Pharmaceuticals announced that the company has received regulatory approval to market a combination of its novel, patent protected and globally-researched sodium glucose co-transporter-2 (SGLT2) inhibitor ...
Glenmark receives ANDA approval for Ranolazine Extended-Release Tablets biospectrumasia
July 09, 2019
It is a generic version of Ranexa® Extended-Release Tablets, 500 mg and 1,000 mg, of Gilead Sciences, Inc.

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page